Compare ASIX & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | KALV |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.9M | 551.2M |
| IPO Year | N/A | N/A |
| Metric | ASIX | KALV |
|---|---|---|
| Price | $17.77 | $15.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $27.83 |
| AVG Volume (30 Days) | 736.2K | ★ 992.0K |
| Earning Date | 02-20-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 35.47 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $1,491,348,000.00 | $1,426,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.59 | $204.16 |
| P/E Ratio | $8.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.10 | $7.30 |
| 52 Week High | $32.58 | $17.30 |
| Indicator | ASIX | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 61.23 | 55.48 |
| Support Level | $17.10 | $15.12 |
| Resistance Level | $17.69 | $16.45 |
| Average True Range (ATR) | 0.59 | 0.90 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 100.00 | 46.65 |
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.